LEGAL STANDARDS FOR POST-MARKET SURVEILLANCE DATA CONFLICTS

1. INTRODUCTION

Post-market surveillance data conflicts arise when information collected after a medical device, pharmaceutical product, diagnostic test, or biotechnology product enters the market is inconsistent, incomplete, or contradictory. For example, a manufacturer's safety report may indicate acceptable performance while hospital records, patient complaints, independent studies, or adverse-event databases suggest an increased risk of injury.

Such conflicts create legal questions concerning patient safety, regulatory reporting, scientific reliability, product liability, and the duty to investigate emerging risks. Organisations must not dismiss contradictory evidence merely because it conflicts with their previous safety conclusions. However, an isolated adverse-event report does not automatically establish that a product caused the reported injury.

2. LEGAL AND REGULATORY FRAMEWORK

A. INDIA: MEDICAL DEVICES RULES, 2017

The Medical Devices Rules, 2017, establish requirements for medical-device safety, performance, vigilance, and post-market surveillance. The relevant provisions and schedules require applicable manufacturers to maintain surveillance procedures, document complaints, and record corrective and preventive actions.

The Central Drugs Standard Control Organisation (CDSCO) oversees medical-device regulation, while the Materiovigilance Programme of India (MvPI), coordinated by the Indian Pharmacopoeia Commission, supports the collection, assessment, and analysis of medical-device adverse-event reports. A CDSCO circular dated 15 May 2024 encouraged licence holders to use MvPI for reporting adverse events and serious adverse events. <Cite refs={["turn145514search26","turn145514search25"]}/>

B. PHARMACEUTICAL PRODUCTS

For medicines and biological products, the applicable provisions of the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and relevant pharmacovigilance requirements must be considered. Manufacturers and marketing authorisation holders must comply with the reporting, safety-monitoring, and corrective-action duties applicable to their products.

C. EUROPEAN UNION

Articles 83–86 of Regulation (EU) 2017/745 on medical devices establish post-market surveillance, post-market surveillance reporting, periodic safety update reporting, and trend-reporting requirements. Article 83 requires systematic collection and analysis of relevant safety and performance data throughout the device's lifetime. Findings must inform risk management and appropriate preventive or corrective action. <Cite refs={["turn145514search24","turn145514search4"]}/>

3. PRINCIPAL LEGAL STANDARDS FOR RESOLVING DATA CONFLICTS

A. EVIDENCE-BASED INVESTIGATION

Conflicting evidence should be evaluated according to its reliability, completeness, source, methodology, sample size, and clinical relevance. Investigators should assess whether differences result from reporting bias, inconsistent definitions, incomplete follow-up, product variations, or genuine safety signals.

B. TRANSPARENT DOCUMENTATION

Manufacturers should preserve original reports, document methodological differences, record their reasoning, and maintain an auditable history of safety assessments. Material contradictory findings should not be selectively omitted from regulatory submissions.

C. TIMELY REGULATORY REPORTING

Where applicable reporting criteria are met, an organisation should report serious adverse events or emerging safety concerns within the legally prescribed timeframe. Investigation of conflicting evidence must not become an unjustified reason to delay a mandatory notification.

D. PROPORTIONATE CORRECTIVE ACTION

Depending on the evidence and applicable law, appropriate action may include additional investigation, enhanced monitoring, revised warnings, corrective notices, field safety corrective action, suspension, or recall. The response should reflect the severity, likelihood, and uncertainty of the risk.

E. CAUSATION AND ACCOUNTABILITY

An adverse event occurring after product use does not necessarily prove causation. Nevertheless, manufacturers and regulators must evaluate credible evidence appropriately. Negligent failure to investigate, concealment of material safety information, or unjustified delay in required action may create regulatory or civil liability where the relevant legal elements are established.

4. RELEVANT CASE LAWS

The following decisions establish analogous principles concerning scientific evidence, professional standards, and product safety. They are not direct precedents establishing a comprehensive legal test for post-market surveillance data conflicts.

A. A.P. POLLUTION CONTROL BOARD v. PROF. M.V. NAYUDU (1999) — ANALOGOUS SCIENTIFIC-EVIDENCE AUTHORITY

The Supreme Court of India highlighted the challenges courts face when resolving disputes involving complex scientific and technical evidence. Its reasoning supports the use of competent expertise and careful assessment of conflicting evidence in biotechnology and medical-product safety disputes.

B. JACOB MATHEW v. STATE OF PUNJAB (2005) — ANALOGOUS PROFESSIONAL-STANDARD AUTHORITY

The Supreme Court explained principles governing professional negligence and the importance of assessing conduct against the applicable standard of care. The judgment is relevant when evaluating whether a responsible professional or institution acted reasonably in interpreting safety information.

C. SAMIRA KOHLI v. DR. PRABHA MANCHANDA (2008) — ANALOGOUS PATIENT-RIGHTS AUTHORITY

The Supreme Court emphasised informed consent in medical treatment. Its principles support appropriate disclosure of material risks when emerging safety information changes the risk profile of a medical intervention.

D. INDIAN MEDICAL ASSOCIATION v. V.P. SHANTHA (1995) — ANALOGOUS CONSUMER-PROTECTION AUTHORITY

The Supreme Court examined the applicability of consumer-protection law to medical services. The judgment provides context for accountability where deficient services cause legally recognised harm, although it does not specifically govern manufacturer surveillance databases.

E. DONOGHUE v. STEVENSON (1932) — ANALOGOUS PRODUCT-SAFETY AUTHORITY

The House of Lords recognised a manufacturer's duty of care toward the ultimate consumer. The principle may support liability where a manufacturer negligently fails to address a foreseeable product hazard, subject to applicable law and proof of causation.

F. VELLORE CITIZENS' WELFARE FORUM v. UNION OF INDIA (1996) — ANALOGOUS PRECAUTIONARY-PRINCIPLE AUTHORITY

The Supreme Court recognised the precautionary principle as an important feature of Indian environmental law. Its relevance is indirect but illustrates why credible risks should receive appropriate preventive attention despite scientific uncertainty.

5. PRACTICAL COMPLIANCE REQUIREMENTS

Organisations should maintain a centralised adverse-event database, establish procedures for reconciling conflicting reports, document causality assessments, preserve audit trails, and escalate significant safety signals to qualified reviewers. They should also maintain clear reporting timelines, evaluate whether warnings or instructions require revision, and document the reasons for corrective-action decisions.

6. CONCLUSION

Post-market surveillance data conflicts require transparent investigation, scientifically defensible evaluation, timely reporting, and proportionate risk management. Indian medical-device and pharmaceutical frameworks provide mechanisms for monitoring safety and addressing emerging risks, while international frameworks offer additional models for systematic surveillance. Courts may apply established principles of negligence, product safety, professional responsibility, and scientific evidence. Effective compliance requires neither automatic acceptance nor automatic rejection of contradictory reports, but a documented, impartial assessment that prioritises patient safety and regulatory accountability.